Imperial College London

ProfessorEricAlton

Faculty of MedicineNational Heart & Lung Institute

Chair in Gene Therapy
 
 
 
//

Contact

 

+44 (0)20 7594 7937e.alton

 
 
//

Location

 

Emmanuel Kaye BuildingRoyal Brompton Campus

//

Summary

 

Summary

Eric Alton is Professor of Gene Therapy and Respiratory Medicine, National Heart & Lung Institute, Imperial College London and Honorary Consultant Physician, Royal Brompton Hospital

Professor Alton was educated at Jesus College, Cambridge and Westminster Medical School and subsequently undertook six years of general medical training.  Over the last fifteen years, he has been involved in developing gene therapy for cystic fibrosis and angiogenesis, including three clinical trials.

Professor Alton coordinates the UK CF Gene Therapy Consortium which brings together the three centres in the UK (Edinburgh and Oxford Universities and Imperial College), including approximately 80 clinicians and scientists focused on this problem.

 

Publications

Journals

Smith WD, Bardin E, Cameron L, et al., 2017, Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis, Fems Microbiology Letters, Vol:364, ISSN:0378-1097

Alton EWFW, Beekman JM, Boyd AC, et al., 2017, Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis, Thorax, Vol:72, ISSN:0040-6376, Pages:137-147

Conference

Meng C, Alton E, Boyd C, et al., 2017, Quantification of vector shedding after transduction of murine lungs with F/HN-pseudotyped lentivirus, Annual Conference of the British-Society-for-Gene-and-Cell-Therapy / Joint UK-Regenerative-Medicine-Platform Meeting, MARY ANN LIEBERT, INC, Pages:A12-A12, ISSN:1043-0342

Paul-Smith MC, Pytel KM, Gelinas J-F, et al., 2017, The lung as a factory to produce secreted intrapulmonary and circulatory proteins, Annual Conference of the British-Society-for-Gene-and-Cell-Therapy / Joint UK-Regenerative-Medicine-Platform Meeting, MARY ANN LIEBERT, INC, Pages:A11-A12, ISSN:1043-0342

Pytel KM, Chan M, Meng C, et al., 2016, Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency., Annual Conference of the British-Society-for-Gene-and-Cell-Therapy, MARY ANN LIEBERT, INC, Pages:A19-A19, ISSN:1043-0342

More Publications